```html

Radiation‑Induced Skin Injury (Radiodermatitis) – A Patient‑Friendly Guide

Overview

Radiation‑induced skin injury, also called **radiodermatitis** or **radiation dermatitis**, is damage to the skin that occurs after exposure to ionizing radiation. It is most commonly seen in patients receiving external‑beam radiation therapy (EBRT) for cancer, but can also result from:

• Internal radiation (brachytherapy, radioactive iodine)
• Fluoroscopy‑guided procedures
• Accidental occupational or environmental exposure

Anyone who undergoes therapeutic radiation can develop skin changes, yet the likelihood varies widely. According to the National Cancer Institute, up to 95 % of patients report some degree of skin reaction during a typical 6‑week course of EBRT.

Symptoms

Radiodermatitis progresses through stages, from mild erythema to ulceration. Symptoms may appear within days to weeks after the first radiation session and can continue to evolve for months.

Acute (early) reactions – typically within 1–4 weeks

• Redness (erythema): Pink to bright red skin, similar to a mild sunburn.
• Warmth and tenderness: The area may feel hot or uncomfortable to touch.
• Dry desquamation: Flaking or peeling of the outer skin layer without moisture.
• Moist (wet) desquamation: Oozing, weeping patches where the epidermis has broken down.
• Itching (pruritus): Common especially when skin begins to dry and peel.
• Pain or burning sensation: Ranges from mild discomfort to severe pain.

Chronic (late) reactions – weeks to years after exposure

• Fibrosis: Thickened, stiff skin that may limit mobility.
• Telangiectasia: Small, visible blood vessels (spider veins) on the surface.
• Pigment changes: Hyperpigmentation (darkening) or hypopigmentation (lightening).
• Ulceration or necrosis: Deep, non‑healing sores that can expose underlying tissue.
• Secondary skin cancers: Rare but documented in highly irradiated areas.

Causes and Risk Factors

Radiodermatitis results from the interaction of ionizing radiation with skin cells, DNA, and blood vessels. The following factors influence severity:

• Radiation dose: Higher total dose (measured in Gray, Gy) and larger fraction size increase risk.
• Treatment volume: Larger fields expose more skin.
• Radiation type: Photon (X‑ray) and electron beams differ in depth of penetration; electron therapy often spares deeper tissues but can cause more superficial injury.
• Patient age: Older adults have thinner skin and slower healing.
• Skin type: Fitzpatrick skin types I–III (fair skin) are more prone to erythema; darker skin may develop more pronounced hyperpigmentation.
• Comorbidities: Diabetes, vascular disease, connective‑tissue disorders, and immunosuppression delay healing.
• Concurrent chemotherapy: Certain agents (e.g., 5‑FU, paclitaxel) act as radiosensitizers, worsening skin toxicity.
• Smoking and poor nutrition: Both impair microcirculation and cellular repair.
• Site of radiation: Areas with folds (axillae, groin) or thin soft tissue (head & neck) are more vulnerable.

Diagnosis

Radiodermatitis is primarily a clinical diagnosis made by visual inspection and patient history.

Clinical assessment

• Inspection of the irradiated field for erythema, desquamation, ulceration, or fibrosis.
• Palpation to assess tenderness, induration, or temperature changes.
• Documentation using standardized grading scales, such as:
• CTCAE (Common Terminology Criteria for Adverse Events) – Grades 1–4.
• RTOG/EORTC (Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer) skin toxicity scale.

Adjunct tests (used when diagnosis is uncertain or complications suspected)

• Skin biopsy: To rule out infection, secondary malignancy, or other dermatoses.
• Culture & sensitivity: When there is purulent discharge, indicating bacterial infection.
• Imaging (ultrasound or MRI): If deep tissue involvement, osteoradionecrosis, or ulcer extension is a concern.

Treatment Options

Treatment aims to relieve symptoms, promote healing, and prevent infection. Management is staged according to severity.

General measures for all grades

• Gentle skin care: Use lukewarm water, mild fragrance‑free cleansers, and pat dry.
• Avoid irritants: No alcohol‑based lotions, strong soaps, or abrasive scrubbing.
• Moisturize: Apply a thin layer of emollient (e.g., petroleum jelly, dimethicone‑based cream) several times daily.
• Clothing: Wear loose, soft fabrics; avoid tight belts or straps over the treated area.

Grade 1–2 (mild to moderate) – topical therapy

• Topical corticosteroids: Low‑to‑mid potency (hydrocortisone 1 % or triamcinolone 0.1 %). Reduces inflammation and itching.
• Barrier creams: Zinc oxide or dimethicone to protect against friction.
• Silicone gel sheets: Useful for preventing hypertrophic scarring once the wound has closed.

Grade 3–4 (severe) – advanced care

• Wet dressings: Non‑adherent gauze soaked in sterile saline or hydrogel, changed daily.
• Topical antimicrobial agents: Mupirocin 2 % ointment for suspected bacterial colonization.
• Systemic antibiotics: Oral or IV therapy if cultures confirm infection.
• Debridement: Gentle mechanical or enzymatic removal of necrotic tissue by a wound‑care specialist.
• Hyperbaric oxygen therapy (HBOT): Evidence from the Cochrane review (2021) suggests HBOT can accelerate healing of radiation‑induced soft‑tissue injury.
• Topical growth factors: Becaplermin (recombinant PDGF) has shown benefit in partial‑thickness radiation ulcers.

Adjunctive and supportive therapies

• Analgesics: NSAIDs for mild pain; low‑dose opioids for severe burning.
• Pruritus control: Oral antihistamines (diphenhydramine) or topical menthol.
• Physical therapy: When fibrosis limits range of motion, supervised stretching maintains function.

Living with Radiation‑Induced Skin Injury

Effective self‑care can reduce discomfort and improve healing.

• Daily skin checks: Inspect the irradiated area each morning and evening for new redness, drainage, or odor.
• Hydration: Aim for ≥2 L of water per day; well‑hydrated skin is more resilient.
• Nutrition: Prioritize protein (lean meat, legumes, dairy) and vitamin C/Zinc, which support collagen synthesis.
• Avoid sun exposure: UV rays worsen erythema. Use broad‑spectrum sunscreen (SPF 30+) on non‑irradiated surrounding skin only; do NOT apply directly over open wounds.
• No heat: Avoid hot tubs, heating pads, or intense exercise that raises skin temperature in the treated zone.
• Smoking cessation: Improves microvascular flow and accelerates repair.
• Follow‑up appointments: Keep all scheduled radiation oncology visits; early detection of worsening injury allows prompt intervention.

Prevention

While radiation therapy cannot be avoided in many cancers, several strategies can lower the risk of severe skin injury.

• Radiation planning: Modern techniques (Intensity‑Modulated Radiation Therapy – IMRT, Volumetric Modulated Arc Therapy – VMAT) shape dose distribution to spare normal skin.
• Fractionation: Smaller daily doses (e.g., 1.8 Gy vs. 2.5 Gy) reduce peak skin exposure.
• Prophylactic skin care: Begin gentle moisturizing 1–2 weeks before treatment starts.
• Topical steroids pre‑emptively: Some trials support low‑dose mometasone 0.1 % beginning at week 2 of radiation for breast cancer patients (Mayo Clinic, 2020).
• Education: Patients who receive written instructions on skin care have a 30 % lower rate of Grade ≥2 dermatitis (Cleveland Clinic study, 2019).

Complications

If not properly managed, radiodermatitis can lead to serious outcomes:

• Infection: Bacterial (Staphylococcus aureus, Pseudomonas) or fungal colonization may progress to cellulitis or sepsis.
• Chronic ulceration: Non‑healing wounds increase the risk of osteoradionecrosis, especially in head, neck, and pelvic sites.
• Fibrosis and contracture: Can impair mobility, cause pain, and affect cosmetic appearance.
• Secondary malignancy: Very rare (<0.1 %) but documented in long‑term survivors of high‑dose scalp irradiation.
• Psychosocial impact: Visible skin changes can affect body image and quality of life; referral to counseling may be needed.

When to Seek Emergency Care

---

**Sources**: Mayo Clinic, National Cancer Institute, CDC, NIH (NCI), WHO, Cleveland Clinic, Cochrane Database of Systematic Reviews, peer‑reviewed journals (Radiotherapy & Oncology, JAMA Dermatology). All information is for educational purposes and does not replace professional medical advice.

```